Hypha Discovery is a microbial technology company helping partners in pharmaceutical and agrochemical R&D succeed through the discovery and production of microbial and mammalian metabolites. We are experts in the scalable production of DMPK metabolites and generation of polar analogues, and are also a leading provider of unique natural product screening libraries and associated services.
NEWS & EVENTS
21st-25th August, Philadelphia, PA
come and meet us at Booth 536
28th August – 1st September, Manchester,UK
Hypha presented a joint poster with Incyte at the 2016 Drug Discovery Chemistry conference in San Diego. The poster titled “Biocatalytic C-H Activation of the JAK Inhibitor Ruxolitinib” describes how Hypha’s microbial-based biocatalytic technology was applied to produce an array of hydroxylated and further oxidised keto metabolites of first-in-class JAK inhibitor ruxolitinib. Download a copy here